$CANF reported Phase IIa data in advanced pancreatic ductal adenocarcinoma showing its A3 adenosine receptor agonist namodenoson met the primary safety endpoint in 20 heavily pretreated patients with no new safety signals and good tolerability, while survival outcomes remain immature with one-third of patients alive at data cut-off, supporting continued clinical development as follow-up matures.
Market Data 
Markets 
AI
